Case Study: Underwriters of Thermo Fisher Scientific Offering

Goldman Sachs Spearheads Biotech Leader’s US$1.7 Billion Offering

O’Melveny represented Goldman Sachs & Co. LLC, as representative of the underwriters, in a registered public offering by Thermo Fisher Scientific Inc. (Thermo Fisher) of approximately US$1.7 billion of its common stock. Additionally, O’Melveny represented Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the underwriters, in a registered public offering by Thermo Fisher of US$1.5 billion aggregate principal amount of notes, consisting of US$750 million aggregate principal amount of 3.200 percent Senior Notes due 2027, and US$750 million aggregate principal amount of 4.100 percent Senior Notes due 2047. Thermo Fisher intends to use all of the net proceeds of the offerings to fund a portion of the consideration payable for its US$7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. View More Case Studies